Artur Prusaczyk
Research Subjects
Research Interests
Artur Prusaczyk has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Adam Kiljańczyk
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland
5 shared publications - Andrzej Jasiewicz
Genetic Counseling Center, Subcarpatian Oncological Hospital, 18 Bielawskiego St, 36-200 Brzozów, Poland
5 shared publications - Anna Jakubowska
Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
5 shared publications - Cezary Cybulski
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland
5 shared publications - Dariusz Godlewski
OPEN, Kazimierza Wielkiego 24 Str., 61-863 Poznań, Poland
5 shared publications - Ewa Kilar-Kobierzycka
Department of Oncology, District Specialist Hospital, Leśna 27-29 St, 58-100 Świdnica, Poland
5 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by MDPI AG in Preprints.org
Combined Effects of Selenium, Arsenic, and CAT rs1001179 Genotype on Cancer Risk in Women with Familial Breast Cancer Predisposition
(1) Background: Selenium (Se) and arsenic (As) influence oxidative stress pathways and may jointly affect cancer risk. We investigated whether Se and As status, individually and in combination, are associated with cancer incidence in women with familial breast cancer predisposition. (2) Methods: In this multicenter prospective study, 6134 BRCA1-negative women aged ≥40 years with hereditary breast cancer predisposition were recruited from 16 genetic clinics in Poland. Blood Se and As concentrations were measured repeatedly during follow-up (6–60 months). Primary analyses evaluated cancer risk across combined Se and As strata within a predefined optimal Se range (98–108 µg/L), including analyses stratified by CAT rs1001179 genotype. Exploratory analyses assessed a composite Risk Index (RI = Se + As × 50). Associations with incident cancer were examined using multivariable Cox regression models. (3) Results: Among 6134 participants, 4847 (79.0%) completed follow-up. The lowest cancer risk was observed in women with Se concentrations of 98–108 µg/L and As concentrations of 0.57–0.75 µg/L. Compared with women with As concentrations >1.07 µg/L, this subgroup showed a lower cancer hazard (HR 3.46; 95% CI 1.28–9.32). Associations were stronger when Se, As, and CAT genotype were analyzed jointly (HR 4.74; 95% CI 1.44–15.53). The RI was also associated with cancer risk (HR 4.51; 95% CI 1.72–11.83). (4) Conclusions: Cancer risk varied according to combined selenium and arsenic status. Stronger associations observed after CAT stratification support a potential role for oxidative stress–related gene–environment interactions in cancer susceptibility.
- 6 July 2026
- Published by MDPI AG in Preprints.org
Open AccessCombined Effects of Selenium, Arsenic, and CAT rs1001179 Genotype on Cancer Risk in Women with Familial Breast Cancer Predisposition
(1) Background: Selenium (Se) and arsenic (As) influence oxidative stress pathways and may jointly affect cancer risk. We investigated whether Se and As status, individually and in combination, are associated with cancer incidence in women with familial breast cancer predisposition. (2) Methods: In this multicenter prospective study, 6134 BRCA1-negative women aged ≥40 years with hereditary breast cancer predisposition were recruited from 16 genetic clinics in Poland. Blood Se and As concentrations were measured repeatedly during follow-up (6–60 months). Primary analyses evaluated cancer risk across combined Se and As strata within a predefined optimal Se range (98–108 µg/L), including analyses stratified by CAT rs1001179 genotype. Exploratory analyses assessed a composite Risk Index (RI = Se + As × 50). Associations with incident cancer were examined using multivariable Cox regression models. (3) Results: Among 6134 participants, 4847 (79.0%) completed follow-up. The lowest cancer risk was observed in women with Se concentrations of 98–108 µg/L and As concentrations of 0.57–0.75 µg/L. Compared with women with As concentrations >1.07 µg/L, this subgroup showed a lower cancer hazard (HR 3.46; 95% CI 1.28–9.32). Associations were stronger when Se, As, and CAT genotype were analyzed jointly (HR 4.74; 95% CI 1.44–15.53). The RI was also associated with cancer risk (HR 4.51; 95% CI 1.72–11.83). (4) Conclusions: Cancer risk varied according to combined selenium and arsenic status. Stronger associations observed after CAT stratification support a potential role for oxidative stress–related gene–environment interactions in cancer susceptibility.
- Open Access
- 14 July 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (7) , 841
Antioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers
Pathogenic mutations in BRCA1 (BReast CAncer gene 1) confer high risks of both breast (up to 70%) and ovarian (up to 40%) cancers. Zinc (Zn) and copper (Cu) are essential for various physiological functions, including antioxidant reactions. Their balance, reflected in the Zn/Cu ratio, plays a crucial role in maintaining redox homeostasis, which is vital for cancer prevention. This study examines the antioxidant properties of Zn and Cu, specifically focusing on the blood Zn/Cu ratio as a potential marker for cancer risk among BRCA1 mutation carriers. The study cohort consisted of 989 initially unaffected women, followed up for 7.5 years. Blood samples were analyzed using inductively coupled plasma mass spectrometry. Although individual Zn and Cu levels did not significantly correlate with overall cancer risk, those women with a Zn/Cu ratio above 6.38 experienced a significantly lower cancer risk than women with a ratio below this cut-off point. This suggests that the Zn/Cu ratio may be a valuable biomarker for cancer prevention in this high-risk group. Given the increased cancer risk in BRCA1 mutation carriers, optimizing Zn and Cu levels through dietary and active interventions could provide a preventive strategy.
- 14 July 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (7) , 841
Open AccessAntioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers
Pathogenic mutations in BRCA1 (BReast CAncer gene 1) confer high risks of both breast (up to 70%) and ovarian (up to 40%) cancers. Zinc (Zn) and copper (Cu) are essential for various physiological functions, including antioxidant reactions. Their balance, reflected in the Zn/Cu ratio, plays a crucial role in maintaining redox homeostasis, which is vital for cancer prevention. This study examines the antioxidant properties of Zn and Cu, specifically focusing on the blood Zn/Cu ratio as a potential marker for cancer risk among BRCA1 mutation carriers. The study cohort consisted of 989 initially unaffected women, followed up for 7.5 years. Blood samples were analyzed using inductively coupled plasma mass spectrometry. Although individual Zn and Cu levels did not significantly correlate with overall cancer risk, those women with a Zn/Cu ratio above 6.38 experienced a significantly lower cancer risk than women with a ratio below this cut-off point. This suggests that the Zn/Cu ratio may be a valuable biomarker for cancer prevention in this high-risk group. Given the increased cancer risk in BRCA1 mutation carriers, optimizing Zn and Cu levels through dietary and active interventions could provide a preventive strategy.
- Open Access
Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 Carriers
Breast cancer and ovarian cancer pose a significant risk for BRCA1 carriers, with limited risk-reduction strategies. While improved screening helps in the early detection of breast cancer, preventive measures remain elusive. Emerging evidence suggests a potential link between iodine levels and modulation of cancer risk, but comprehensive studies are scarce. We conducted a prospective study among 989 BRCA1 carriers to assess the association between blood iodine levels and breast and ovarian cancer risk. Using inductively coupled plasma mass spectrometry, we measured blood iodine levels and observed a negative association with breast cancer risk, with a significantly lower risk observed in quartile 4 (iodine > 38.0 µg/L) compared with quartile 1 (iodine < 30 µg/L) (HR = 0.49; 95%CI: 0.27–0.87; p = 0.01). Conversely, a suggestive increase in ovarian cancer risk was observed at higher iodine levels (HR = 1.91; 95%CI: 0.64–5.67; p = 0.25). No significant association was found between iodine levels and overall cancer risk. Our results suggest the potential of iodine to reduce breast cancer risk in BRCA1 carriers after prophylactic oophorectomy but require further validation and investigation of its effect on ovarian cancer risk and overall mortality. These findings highlight the need for personalized strategies to manage cancer risk in BRCA1 carriers.
Open AccessBlood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 Carriers
Breast cancer and ovarian cancer pose a significant risk for BRCA1 carriers, with limited risk-reduction strategies. While improved screening helps in the early detection of breast cancer, preventive measures remain elusive. Emerging evidence suggests a potential link between iodine levels and modulation of cancer risk, but comprehensive studies are scarce. We conducted a prospective study among 989 BRCA1 carriers to assess the association between blood iodine levels and breast and ovarian cancer risk. Using inductively coupled plasma mass spectrometry, we measured blood iodine levels and observed a negative association with breast cancer risk, with a significantly lower risk observed in quartile 4 (iodine > 38.0 µg/L) compared with quartile 1 (iodine < 30 µg/L) (HR = 0.49; 95%CI: 0.27–0.87; p = 0.01). Conversely, a suggestive increase in ovarian cancer risk was observed at higher iodine levels (HR = 1.91; 95%CI: 0.64–5.67; p = 0.25). No significant association was found between iodine levels and overall cancer risk. Our results suggest the potential of iodine to reduce breast cancer risk in BRCA1 carriers after prophylactic oophorectomy but require further validation and investigation of its effect on ovarian cancer risk and overall mortality. These findings highlight the need for personalized strategies to manage cancer risk in BRCA1 carriers.
- Open Access
- 16 May 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (5) , 609
Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers
BRCA1 mutations predispose women to breast and ovarian cancer. The anticancer effect of zinc is typically linked to its antioxidant abilities and protecting cells against oxidative stress. Zinc regulates key processes in cancer development, including DNA repair, gene expression, and apoptosis. We took a blood sample from 989 female BRCA1 mutation carriers who were initially unaffected by cancer and followed them for a mean of 7.5 years thereafter. There were 172 incident cases of cancer, including 121 cases of breast cancer, 29 cases of ovarian cancers, and 22 cancers at other sites. A zinc level in the lowest tertile was associated with a modestly higher risk of ovarian cancer compared to women with zinc levels in the upper two tertiles (HR = 1.65; 95% CI 0.80 to 3.44; p = 0.18), but this was not significant. Among those women with zinc levels in the lowest tertile, the 10-year cumulative risk of ovarian cancer was 6.1%. Among those in the top two tertiles of zinc level, the ten-year cumulative risk of ovarian cancer was 4.7%. There was no significant association between zinc level and breast cancer risk. Our preliminary study does not support an association between serum zinc level and cancer risk in BRCA1 mutation carriers.
- 16 May 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (5) , 609
Open AccessZinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers
BRCA1 mutations predispose women to breast and ovarian cancer. The anticancer effect of zinc is typically linked to its antioxidant abilities and protecting cells against oxidative stress. Zinc regulates key processes in cancer development, including DNA repair, gene expression, and apoptosis. We took a blood sample from 989 female BRCA1 mutation carriers who were initially unaffected by cancer and followed them for a mean of 7.5 years thereafter. There were 172 incident cases of cancer, including 121 cases of breast cancer, 29 cases of ovarian cancers, and 22 cancers at other sites. A zinc level in the lowest tertile was associated with a modestly higher risk of ovarian cancer compared to women with zinc levels in the upper two tertiles (HR = 1.65; 95% CI 0.80 to 3.44; p = 0.18), but this was not significant. Among those women with zinc levels in the lowest tertile, the 10-year cumulative risk of ovarian cancer was 6.1%. Among those in the top two tertiles of zinc level, the ten-year cumulative risk of ovarian cancer was 4.7%. There was no significant association between zinc level and breast cancer risk. Our preliminary study does not support an association between serum zinc level and cancer risk in BRCA1 mutation carriers.
- Open Access
Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers
BRCA1 mutations substantially elevate the risks of breast and ovarian cancer. Various modifiers, including environmental factors, can influence cancer risk. Lead, a known carcinogen, has been associated with various cancers, but its impact on BRCA1 carriers remains unexplored. A cohort of 989 BRCA1 mutation carriers underwent genetic testing at the Pomeranian Medical University, Poland. Blood lead levels were measured using inductively coupled plasma mass spectrometry. Each subject was assigned to a category based on their tertile of blood lead. Cox regression analysis was used to assess cancer risk associations. Elevated blood lead levels (>13.6 μg/L) were associated with an increased risk of ovarian cancer (univariable: HR = 3.33; 95% CI: 1.23–9.00; p = 0.02; multivariable: HR = 2.10; 95% CI: 0.73–6.01; p = 0.17). No significant correlation was found with breast cancer risk. High blood lead levels are associated with increased risk of ovarian cancer in BRCA1 carriers, suggesting priority for preventive salpingo-oophorectomy. Potential risk reduction strategies include detoxification. Validation in diverse populations and exploration of detoxification methods for lowering lead levels are required.
Open AccessBlood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers
BRCA1 mutations substantially elevate the risks of breast and ovarian cancer. Various modifiers, including environmental factors, can influence cancer risk. Lead, a known carcinogen, has been associated with various cancers, but its impact on BRCA1 carriers remains unexplored. A cohort of 989 BRCA1 mutation carriers underwent genetic testing at the Pomeranian Medical University, Poland. Blood lead levels were measured using inductively coupled plasma mass spectrometry. Each subject was assigned to a category based on their tertile of blood lead. Cox regression analysis was used to assess cancer risk associations. Elevated blood lead levels (>13.6 μg/L) were associated with an increased risk of ovarian cancer (univariable: HR = 3.33; 95% CI: 1.23–9.00; p = 0.02; multivariable: HR = 2.10; 95% CI: 0.73–6.01; p = 0.17). No significant correlation was found with breast cancer risk. High blood lead levels are associated with increased risk of ovarian cancer in BRCA1 carriers, suggesting priority for preventive salpingo-oophorectomy. Potential risk reduction strategies include detoxification. Validation in diverse populations and exploration of detoxification methods for lowering lead levels are required.
- Open Access
- 21 February 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (5) , 3831
Health Care Organization in Poland in Light of the Refugee Crisis Related to the Military Conflict in Ukraine
Background: Poland is witnessing a migration crisis caused by the ongoing military conflict in Ukraine. In addition to housing and necessities, 1.8 million Ukrainians that had taken refuge in Poland must have access to medical care. We aim to propose a strategy for implementing the changes in the Polish health care system in response to the Ukrainian refugee crisis. Methods: A literature review on organizational changes in the functioning of health care systems during the migration crises worldwide in recent years and brainstorming in order to develop a strategy for implementing changes in the Polish health care system in response to the Ukrainian refugee crisis. Results: The proposed strategy for implementing the changes in the Polish health care system is based on building health care resilience and adaptation to different crises. The operational objectives of organization-related activities are: (1) preparation of medical facilities to provide help for refugees, (2) development and implementation of the communication system, (3) implementation of available digital solutions, (4) organization of the diagnostic and medical services, (5) and implementation of changes in the management of medical facilities. Conclusions: Urgent reorganization is required to respond to an unavoidable increase in the demand for health care services.
- 21 February 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (5) , 3831
Open AccessHealth Care Organization in Poland in Light of the Refugee Crisis Related to the Military Conflict in Ukraine
Background: Poland is witnessing a migration crisis caused by the ongoing military conflict in Ukraine. In addition to housing and necessities, 1.8 million Ukrainians that had taken refuge in Poland must have access to medical care. We aim to propose a strategy for implementing the changes in the Polish health care system in response to the Ukrainian refugee crisis. Methods: A literature review on organizational changes in the functioning of health care systems during the migration crises worldwide in recent years and brainstorming in order to develop a strategy for implementing changes in the Polish health care system in response to the Ukrainian refugee crisis. Results: The proposed strategy for implementing the changes in the Polish health care system is based on building health care resilience and adaptation to different crises. The operational objectives of organization-related activities are: (1) preparation of medical facilities to provide help for refugees, (2) development and implementation of the communication system, (3) implementation of available digital solutions, (4) organization of the diagnostic and medical services, (5) and implementation of changes in the management of medical facilities. Conclusions: Urgent reorganization is required to respond to an unavoidable increase in the demand for health care services.
- Open Access
- 4 November 2022
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 22 (S3) , 466
A proposal to implement incentive systems for local authorities to prevent the further occurrence of excess non-covid deaths during the covid 19 pandemic COVID-19 pandemic
- 4 November 2022
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 22 (S3) , 466
Open AccessA proposal to implement incentive systems for local authorities to prevent the further occurrence of excess non-covid deaths during the covid 19 pandemic COVID-19 pandemic
- Open Access
- 4 November 2022
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 22 (S3) , 315
Competency deficits of medical and peri-medical staff in medical facilities, including new tasks associated with the COVID-19 epidemic
- 4 November 2022
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 22 (S3) , 315
Open AccessCompetency deficits of medical and peri-medical staff in medical facilities, including new tasks associated with the COVID-19 epidemic
- Open Access
- 1 September 2021
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 21 (S1) , 199
Factors influencing screening uptake rate in healthcare institutions in Poland
- 1 September 2021
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 21 (S1) , 199
Open AccessFactors influencing screening uptake rate in healthcare institutions in Poland
- Open Access
- 29 October 2019
- Published by Springer Nature in Research Square
Anxiety and depression in patients with chronic cardiovascular disease—factors differentiating rural and urban subpopulations
Background. People suffering from cardiovascular diseases (CVD) increasingly experience depression and anxiety disorders. Therefore, it is essential to improve identification strategies and methods of coping for these conditions.Objectives. The aim of the study was to analyse selected variables differentiating rural from urban populations as well as identify potentially increased levels of depression and anxiety.Material and methods. The study was carried out in 193 CVD patients home-cared by a district nurse. Results. Women constituted the majority of respondents (71.7%, n = 81 City-C vs 65.8%, n = 50 Village-V). The median age of the C patients was 76 (range 17-101) vs. 72 (range 18-94) for the V patients. The correlation coefficients displayed significant differences in anxiety, number of cardiologist visits (p = 0.005) and interventions provided by a district nurse (p = 0.03). The rural population stood out in number of home visits, age, assessment of needs and QoL. In addition, a strong relationship between anxiety and age was noted in the rural population (1/OR=1.04; 95% CI: 0.91–0.99), the assessment of satisfied needs (1/OR=293.86; 95% CI: 0.00001–0.56), depression (OR=5.85; 95% CI: 1.58–25.66), QoL in physical (OR=1.56; 95% CI: 1.11–2.33), social (1/OR=1.53; 95% CI: 0.04–0.94) and environmental domains (OR=1.67; 95% CI: 1.06–3.00) as well as between depression and anxiety (OR=4.60; 95% CI: 1.45–16.28), QoL in physical (1/OR=1.39; 95% CI: 0.50–0.97) and psychological (OR=1.37; 95% CI: 1.01–1.93) domains.
- 29 October 2019
- Published by Springer Nature in Research Square
Open AccessAnxiety and depression in patients with chronic cardiovascular disease—factors differentiating rural and urban subpopulations
Background. People suffering from cardiovascular diseases (CVD) increasingly experience depression and anxiety disorders. Therefore, it is essential to improve identification strategies and methods of coping for these conditions.Objectives. The aim of the study was to analyse selected variables differentiating rural from urban populations as well as identify potentially increased levels of depression and anxiety.Material and methods. The study was carried out in 193 CVD patients home-cared by a district nurse. Results. Women constituted the majority of respondents (71.7%, n = 81 City-C vs 65.8%, n = 50 Village-V). The median age of the C patients was 76 (range 17-101) vs. 72 (range 18-94) for the V patients. The correlation coefficients displayed significant differences in anxiety, number of cardiologist visits (p = 0.005) and interventions provided by a district nurse (p = 0.03). The rural population stood out in number of home visits, age, assessment of needs and QoL. In addition, a strong relationship between anxiety and age was noted in the rural population (1/OR=1.04; 95% CI: 0.91–0.99), the assessment of satisfied needs (1/OR=293.86; 95% CI: 0.00001–0.56), depression (OR=5.85; 95% CI: 1.58–25.66), QoL in physical (OR=1.56; 95% CI: 1.11–2.33), social (1/OR=1.53; 95% CI: 0.04–0.94) and environmental domains (OR=1.67; 95% CI: 1.06–3.00) as well as between depression and anxiety (OR=4.60; 95% CI: 1.45–16.28), QoL in physical (1/OR=1.39; 95% CI: 0.50–0.97) and psychological (OR=1.37; 95% CI: 1.01–1.93) domains.